WallStreetZenWallStreetZen
NYSE: CTLT

How to Buy Catalent Stock

Open Broker Account

Catalent Inc

Catalent is a pharmaceutical company located in New Jersey, United States, which is part of the Healthcare sector, and is traded under the ticker CTLT on the NYSE exchange.

Catalent stock last closed at $50.13, up 6.25% from the previous day, and has decreased 61.04% in one year. It has underperformed other stocks in the Drug Manufacturers - Specialty & Generic industry by 0.22 percentage points. Catalent stock is currently +23.2% from its 52-week low of $40.69, and -61.72% from its 52-week high of $130.97.

There are currently 179.96M shares of CTLT outstanding. The market cap of CTLT is $9.02B. In the last 24 hours, 4.89M CTLT shares were traded.

How to Buy Catalent Stock

Not sure how to invest in Catalent stock? Here's how.
  1. Decide where to buy Catalent stock: You need to decide on an online brokerage, but don't worry - we've tested dozens of stock brokerages and apps to help you determine where to buy Catalent stock.
  2. Sign up for a brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've found. It's the best place to buy CTLT stock.
  3. Deposit money your brokerage account: Pick your payment method and add your information.
  4. Research Catalent stock: The Catalent ticker symbol is CTLT. Is Catalent stock a good investment? Should you buy shares of CTLT? How do CTLT's underlying business fundamentals look? Do top analysts think Catalent is a good buy? Why has CTLT's stock price moved recently? (Hint: Our stock research tools can help you understand if CTLT is a good stock to buy).
  5. Execute your CTLT trade: Decide if you will purchase CTLT shares at the current market price or use a limit order to purchase CTLT shares at a specific price.
  6. Get updates on your CTLT position: Create a watchlist to important updates regarding your position in Catalent stock.

Step 1: Decide where to buy Catalent stock

You need an online brokerage account in order to access the NYSE market and buy CTLT shares.

A brokerage account is an investment account that allows you to buy and sell a number of financial instruments, such as stocks, bonds, mutual funds, and ETFs.

Our recommended brokerage: eToro

Based on our experience, eToro is the best online stock brokerage. eToro gives you:

  • You can invest in stocks with 0% commissions: Invest without paying trading commissions.
  • Buy fractional shares: Even if you don't have the money to buy a full share, you can still purchase the stock.
  • Access to world markets: From Tech to Healthcare, New York to Tokyo — you can fill your portfolio with stocks from the world's top stock exchanges.
  • Social investing: eToro has a community with more than 20 million users globally. Talk to, learn from, and copy the unique crypto portfolios of other investors.
  • Security: eToro is a regulated and licensed fintech leader.
  • Buy other assets: Such as ETFs and cryptos.

Get $10 towards your purchase of shares by creating an account with eToro now.

Open eToro Account

Step 2: Sign up for a brokerage account

Now that you've selected your brokerage, you'll need to fill out some personal info so you are able to buy CTLT stock today.

How to Create a New Brokerage Account on eToro

  1. Click here to get started.
  2. Input your personal data to create your new trading account.
  1. Send your info by pressing the "Create Account" button.
Get started with eToro today

Step 3: Deposit money your brokerage account

Check out the walkthrough below for more details depositing money into your new investment account.

Get started with eToro today

Step 4: Research Catalent stock

It's crucial to research stocks prior to buying, so you actually understand the risk and upside.

Overview of key CTLT info

CTLT Price
$50.13
1w %
18.85%
1y %
-61.04%
5y %
25.99%
P/E
21.33x
P/B
1.92x
P/S
1.87x
PEG
0.67x
Revenue
$4.83B
Earnings
$421.00M
Fore. Rev. Growth
9.77%
Fore. Earn. Growth
31.88%
Market Cap
$9.02B
Next Earnings
Jan 30, 2023
Next Dividend
N/A

Catalent Overview

WallStreetZen was created to help average investors perform better fundamental analysis in less time.

You can view all of the due diligence checks on CTLT's stock page.

How is CTLT stock valued?

Investors use a variety of different financial metrics, analyses, models, and charts to gauge CTLT's fair value.

Using relative valuations ratios:

  • CTLT could be overvalued based on its P/E ratio of 21.33x, relative to Drug Manufacturers - Specialty & Generic industry P/E ratio of 19.41x
  • CTLT may be overvalued based on its P/B ratio of 1.92x, relative to Drug Manufacturers - Specialty & Generic industry P/B ratio of 1.78x
  • CTLT may be undervalued based on its PEG ratio of 0.67x

You can access additional valuation analysis on CTLT's stock here.

CTLT Financial Health Overview

Pros:

  • Total CTLT debt is lower than 5 years ago, relative to shareholder equity.
  • There are more short-term assets than short-term liabilities on the CTLT balance sheet.

Cons:

  • CTLT profit margin has gone down from 13.1% to 8.7% in the past year.
  • CTLT has cash burn of 465000000. It does not have sufficient cash and short-term investments to cover this.
  • There are more long-term liabilities than short-term assets on the CTLT balance sheet.
  • CTLT has $345.00M in cash and short term investments. This is not enough to cover its annual cash burn of $465.00M.
  • CTLT has a relatively high debt to equity ratio of 1.17.

Is it a good time to buy Catalent stock?

Out of 8 Wall Street analysts who give recommendations on CTLT, the consensus analyst rating on Catalent is a Buy

Should I buy or sell CTLT stock?

Based on 8 analysts offering ratings for Catalent Inc.
Buy
Strong Buy
4 analysts 50%
Buy
1 analysts 12.5%
Hold
3 analysts 37.5%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Latest CTLT Analyst Ratings

David Toung, a top 19% analyst from Argus Research downgrades CTLT to a hold rating, on Nov 7, 2022.

Tejas Savant, a bottom 5% analyst from Morgan Stanley maintains CTLT with a strong buy rating and lowers their CTLT price target from $120.00 to $81.00, on Nov 3, 2022.

Luke Sergott, a bottom 3% analyst from Barclays maintains CTLT with a strong buy rating and lowers their CTLT price target from $105.00 to $62.00, on Nov 2, 2022.

Derik De Bruin, a top 6% analyst from Bank of America downgrades CTLT to a hold rating and lowers their CTLT price target from $125.00 to $60.00, on Nov 2, 2022.

Sean Dodge, a top 28% analyst from RBC Capital maintains CTLT with a buy rating and lowers their CTLT price target from $125.00 to $73.00, on Nov 2, 2022.

You can dig deeper into what analysts are forecasting on the Catalent stock forecast page.

Metrics for Advanced CTLT Traders

SMA10
44.1
SMA20
44.21
SMA50
61.4
SMA100
81.61
SMA200
92.01
MACD
-4.62
MACD Signal
-6.42
MACD Histogram
1.8
RSI
48.55
Stochastic %K
82.52
Stochastic %D
56.06
StochRSI %K
100
StochRSI %D
91.26

CTLT Performance Metrics

Last year, CTLT earnings were $421.00M. In the last five year, CTLT's earnings have increased by 21.71% per year. This was faster than the Drug Manufacturers - Specialty & Generic industry average of 7.89%.

Last year, CTLT revenue was $4.83B. During the last five year, CTLT's revenue has increased by 17.25% per year. This was slower than the Drug Manufacturers - Specialty & Generic industry average of 44.35%.

Dig into CTLT's earnings and revenue performance here.

What are CTLT insiders up to?

Over the past 12 months, executives and large shareholders at CTLT have sold more shares than they have bought.

Michael J. Grippo, SVP Strategy Corp. Dev. of CTLT, was the latest CTLT insider to sell. They sold $161,349.33 worth of CTLT shares on Oct 31, 2022.

Get more info about who owns CTLT stock here.

Can I get consistent income from CTLT stock?

No, Catalent doesn't provide an income stream by paying out dividends.

Get opinions from other traders

One of the major reasons eToro is our favorite brokerage is because of its social trading community.

Click below to learn what other traders have to say.

Step 5: Execute your CTLT trade

You have two primary options:

  • Market order: A market order is an order to buy or sell a security at the best available price.
    Market orders are mostly the easiest way to buy.
  • Limit order: A limit order enables you to buy or sell a security at a specific price (or better).
    If you want to be certain you're buying or selling at a given price, use a limit order.

Hit the Open button and eToro will place your order.

If you want additional info about investing in stocks on eToro, click the how to video below:

Open eToro Account

Step 6: Get updates on your CTLT position

Now that you own some CTLT stock, you'll want to keep up with your company.

Put CTLT on a watchlist to get notified of important updates regarding your CTLT stock.

CTLT Feed

How to Buy Stock in Catalent

To reiterate, here are the 6 steps to buy stock in Catalent:

  1. Decide where to buy Catalent stock
  2. Sign up for a brokerage account
  3. Deposit money your brokerage account
  4. Research Catalent stock
  5. Execute your CTLT trade
  6. Get updates on your CTLT position

If you require a brokerage account, eToro is our favorite venue.

Get Started with eToro Today

If you want to get the latest news on your investment in Catalent, click below.

NYSE: CTLT
$50.13+2.95 (+6.25%)
Updated Nov 30, 2022
Open eToro Account
NYSE: CTLT
$50.13+2.95 (+6.25%)
Updated Nov 30, 2022
Open eToro Account

FAQ

How much does it cost to buy one Catalent share?

As of Nov 30, 2022, it costs $50.13 to buy one share of Catalent stock.

Remember, eToro's fractional share buying allows you to buy partial shares of stocks and ETFs. Even if you only have $10, you can buy 0.199 shares of CTLT.

Get Started with eToro Today

Is now a good time to buy Catalent stock?

According to 8 Wall Street analysts who monitor Catalent, their consensus recommendation is to buy Catalent stock.

What is the best way to buy Catalent stock?

The best way to buy Catalent stock is within a brokerage account on eToro.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.